BridgeMD
Contribution of PET (positron emission tomography) scans for the preoperative assessment of symptomatic endometriosis lesions: TEP-ENDORUN
EU CTIS ID: 2024-520423-88-00
What this study is testing
To assess the PET scan in the diagnosis of endometriosis lesions compared to surgery in terms of number of lesions diagnosed and locations.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient aged over 18 and under 50
- Patient with symptomatic endometriosis with indication for surgery
- Patient showing at least one typical endometriosis lesion on MRI, greater than 5mm
- Patient accepting surgical management
- Patient having signed an informed consent after information
- Patient affiliate or beneficiary of a social security scheme
You likely can't join if
- Patient who has received an injection with GnRH (gonadotropin-releasing hormone ) analogues for less than 3 months (because it induces the quiescence of the disease which is no longer stimulated by estrogen secretion)
- Use of corticosteroids and anti-inflammatory drugs within 7 days prior to PET scan For patients with a chronic pathology requiring long-term treatment with corticosteroids and/or use of corticosteroids and anti-inflammatory drugs within 7 days prior to PET scan
- Blood glucose > 1.6 g/L e on day of PET Scanner
- Patient with a history of heavy abdominopelvic surgery
- Diabetic patient
- Patient with contraindication to surgery or anesthesia
See the full eligibility criteria
- Patient aged over 18 and under 50
- Patient with symptomatic endometriosis with indication for surgery
- Patient showing at least one typical endometriosis lesion on MRI, greater than 5mm
- Patient accepting surgical management
- Patient having signed an informed consent after information
- Patient affiliate or beneficiary of a social security scheme
- Patient who has received an injection with GnRH (gonadotropin-releasing hormone ) analogues for less than 3 months (because it induces the quiescence of the disease which is no longer stimulated by estrogen secretion)
- Use of corticosteroids and anti-inflammatory drugs within 7 days prior to PET scan For patients with a chronic pathology requiring long-term treatment with corticosteroids and/or use of corticosteroids and anti-inflammatory drugs within 7 days prior to PET scan
- Blood glucose > 1.6 g/L e on day of PET Scanner
- Patient with a history of heavy abdominopelvic surgery
- Diabetic patient
- Patient with contraindication to surgery or anesthesia
- Patient unable to understand the interest of the study
- Patient with contraindications to PET Scanner (major claustrophobia, contraindication or hypersensitivity to 18-FDG or one of its excipients, contraindication or hypersensitivity to Ultravist® or one of its excipients, etc.)
- Patient already included in another therapeutic trial with an experimental molecule
- Persons referred to in articles L1121-5 to L1121-8 of the PHC (public health code) (corresponding to all protected persons: pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, minor, and person making the subject to a legal protection measure: guardianship or curators)
- Positive plasma HCG assay in the days preceding the PET scan;
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.